[ad_1]
Vancouver, British Columbia, June 19, 2021 (Global News Agency) – Core One Lab Company (Comprehensive Education:Cool), (Over-the-counter transactions:CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“the company“) is pleased to announce that its wholly-owned subsidiary Akome Biotech Ltd. (“Akame“) Has begun to develop the next generation of psychedelic drug formulations to reduce nerve damage caused by ischemic stroke.
Akome is a next-generation psychedelic drug formulation used to reduce nerve damage caused by ischemic stroke, also known as AKO001, composed of the psychedelic compound N,N-dimethyltryptamine (DMT) and a specific plant bioactive substance When the composition is provided to the individual immediately after an ischemic stroke, it works in a way of replenishment and relief. A provisional combined patent application for AKO001 has been submitted to the United States Patent and Trademark Office (USPTO) with the application number 63147343.
Ischemia is a condition in which blood vessels are blocked and blood flow stops or decreases. When the blood flow to a certain part of the body decreases, that part of the body cannot get enough oxygen. Most strokes are ischemic in nature, the blood flow through the arteries that supply oxygen-rich blood to the brain is blocked, and brain cells begin to die. Ischemic stroke is the third most common cause of death in the world and the leading cause of disability in adults worldwide. 1The World Health Organization estimates that 17.9 million people worldwide die of stroke each year.
Akome’s specially selected plant bioactive substances and DMT are an ideal combination of compounds to reduce nerve damage caused by ischemic stroke. This…
The full story on Benzinga.com
[ad_2]
Source link
